{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:47:57Z","timestamp":1767134877352,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011782","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000}}],"reference-count":110,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011782.pub2","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T05:42:17Z","timestamp":1512366137000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pentasaccharides for the treatment of deep vein thrombosis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Gustavo MS","family":"Brandao","sequence":"first","affiliation":[{"name":"Faculdade de Medicina de Botucatu; Department of Surgery and Orthopedics; Av. Professor Montenegro Distrito de Rubiao Junior s\/n Botucatu SP Brazil 18618-970"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela R","family":"Junqueira","sequence":"additional","affiliation":[{"name":"University of Alberta; Faculty of Dentistry and Medicine; 8215 112 St NW Suite #1702, College Plaza Edmonton Alberta Canada T6G 2C8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamilton A","family":"Rollo","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Botucatu; Department of Surgery and Orthopedics; Av. Professor Montenegro Distrito de Rubiao Junior s\/n Botucatu SP Brazil 18618-970"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcone L","family":"Sobreira","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Botucatu; Department of Surgery and Orthopedics; Av. Professor Montenegro Distrito de Rubiao Junior s\/n Botucatu SP Brazil 18618-970"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"key":"10.1002\/14651858.CD011782.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Buller HR Destors JM Gallus AS Prins MH Raskob GE Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32] Blood 2009 18","DOI":"10.1182\/blood.V112.11.32.32"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2010.04100.x","article-title":"Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis","volume":"9","author":"Equinox Investigators","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0003|cit3","unstructured":"NCT00311090 Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX) clinicaltrials.gov\/ct2\/show\/NCT00311090"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0004|cit4","unstructured":"A multicentre, randomized, double-blind study comparing the efficacy and safety of once daily (o.d.) Org31540\/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE-DVT). Study No: EFC2441 GlaxoSmithKline Clinical Trial Register 2005"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0006|cit5","doi-asserted-by":"crossref","unstructured":"Buller H Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials Journal of Thrombosis and Haemostasis 2005 Abstract number: P1112","DOI":"10.1182\/blood.V104.11.705.705"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0005|cit6","first-page":"82","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial","volume":"26","author":"Buller","year":"2005","journal-title":"Revue de Medecine Interne"},{"issue":"11","key":"10.1002\/14651858.CD011782.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"Buller","year":"2004","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Buller HR The MATISSE Investigators Efficacy and safety of fondaparinux (ARIXTRA\u00ae) in the initial treatment of venous thromboembolism in obese patients Blood 2004 Abstract 706","DOI":"10.1182\/blood.V104.11.706.706"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Buller HR The Matisse Investigators Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra\u00ae): the Matisse trials Blood 2004 Abstract 705","DOI":"10.1182\/blood.V104.11.705.705"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0010|cit10","unstructured":"The Matisse Investigators The MATISSE-DVT trial, a randomized, double-blind study comparing once-daily fondaparinux (Arixtra) with the low-molecular-weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep-vein thrombosis (DVT) Journal of Thrombosis and Haemostasis 2003 Abstract OC332"},{"issue":"4","key":"10.1002\/14651858.CD011782.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH08-09-0563","article-title":"Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials","volume":"101","author":"Doormaal","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0012|cit12","unstructured":"Persist Investigators A novel long-acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation Blood 2002 Abstract 301"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation","volume":"2","author":"Persist Investigators","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001721-200301000-00011","article-title":"Idraparinux and liver enzymes: observations from the PERSIST trial","volume":"14","author":"Reiter","year":"2003","journal-title":"Blood Coagulation and Fibrinolysis"},{"issue":"22","key":"10.1002\/14651858.CD011782.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/01.CIR.102.22.2726","article-title":"Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A\/ORG31540) with pure anti-factor Xa activity: a phase II evaluation","volume":"102","author":"The Rembrandt Investigators","year":"2000","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD011782.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V108.11.6.6","article-title":"Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep-vein thrombosis or pulmonary embolism","volume":"108","author":"Buller","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD011782.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"The Van Gogh Investigators","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1160\/TH09-12-0870","article-title":"Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial","volume":"104","author":"Doormaal","year":"2010","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(11)61505-5","article-title":"Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial","volume":"379","author":"Buller","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD011782.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2010.03746.x","article-title":"Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion","volume":"8","author":"Paty","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD011782.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/bcp.12009","article-title":"Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis","volume":"75","author":"Trellu","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0022|cit22","unstructured":"A multicentre, randomized, open-label study comparing the efficacy and safety of once daily (o.d.) Org31540\/SR90107A versus adjusted dose intravenous (i.v.) unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE) (MATISSE-PE). Study No: 63123 GlaxoSmithKline Clinical Trial Register 2005"},{"issue":"18","key":"10.1002\/14651858.CD011782.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"Buller","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD011782.pub2-BIB0024|cit24","first-page":"P0424","article-title":"Outcomes in obese patients of pulmonary embolism (PE) and deep vein thrombosis (DVT) treatment with fondaparinux or (LMW) heparins: the Matisse trials","volume":"3","author":"Davidson","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0025|cit25","unstructured":"Davidson BL the Matisse Steering Committee and Investigators Fondaparinux, a pentasaccharide vs unfractionated heparin (UH) or low molecular weight heparin (LMWH) for pulmonary embolism (PE) or deep vein thrombosis (DVT): the Matisse trials [abstract] American Thoracic Society 99th International Conference 2003 A119"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0026|cit26","unstructured":"Matisse Investigators Fondaparinux (Arixtra) in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism - the Matisse clinical outcome studies Blood 2002 Abstract 302"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0027|cit27","first-page":"53","article-title":"Initial outpatient treatment of pulmonary embolism with fondaparinux (Arixtra): the Matisse-Pe trial","volume":"Suppl 2","author":"Piovela","year":"2004","journal-title":"Hematology Journal"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0028|cit28","unstructured":"The Matisse Investigators The MATISSE-PE trial, a multicenter, randomized, open study comparing once-daily fondaparinux (Arixtra\u00ae) with adjusted-dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism Journal of Thrombosis and Haemostasis 2003 Abstract number OC331"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Nakamura M Okano Y Minamigichi H Tsujimoto H Nakajima H Kunieda T Clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients Chest 2010","DOI":"10.1378\/chest.9982"},{"issue":"6","key":"10.1002\/14651858.CD011782.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1253\/circj.CJ-10-1036","article-title":"Multidetector-row computed tomography-based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients","volume":"75","author":"Nakamura","year":"2011","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Buller HR Once weekly subcutaneous idraparinux versus placebo in the extended treatment of deep-vein thrombosis or pulmonary embolism. The Van Gogh Investigators Blood 2006 172","DOI":"10.1182\/blood.V108.11.571.571"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Buller HR The Van Gogh Investigators Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep-vein thrombosis or pulmonary embolism Blood 2006 6 7","DOI":"10.1182\/blood.V108.11.6.6"},{"issue":"6","key":"10.1002\/14651858.CD011782.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00228-008-0463-0","article-title":"Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials","volume":"64","author":"Harenberg","year":"2008","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD011782.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa067703","article-title":"Extended prophylaxis of venous thromboembolism with idraparinux","volume":"357","author":"The Van Gogh Investigators","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011782.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/pbc.23011","article-title":"FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age","volume":"57","author":"Young","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0036|cit36","unstructured":"Brasil. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) Price of medicines commercialised in the country novoportal.anvisa.gov.br\/listas-de-precos"},{"issue":"3","key":"10.1002\/14651858.CD011782.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0897190010362170","article-title":"Fondaparinux (Arixtra\u00ae), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?","volume":"23","author":"Badger","year":"2010","journal-title":"Journal of Pharmacy Practice"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0038|cit38","first-page":"364S-70S","article-title":"New pentasaccharides for prophylaxis of deep vein thrombosis","volume":"124","author":"Bauer","year":"2003","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0039|cit39","first-page":"1","article-title":"New oral anticoagulants in development: potential for improved safety profiles","volume":"7","author":"Bauer","year":"2010","journal-title":"Reviews in Neurological Diseases"},{"issue":"2","key":"10.1002\/14651858.CD011782.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/157489010791515269","article-title":"Old versus new anticoagulants: focus on pharmacology","volume":"5","author":"Benmira","year":"2010","journal-title":"Recent Patents on Cardiovascular Drug Discovery"},{"issue":"5","key":"10.1002\/14651858.CD011782.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12179","article-title":"Fondaparinux-associated heparin-induced thrombocytopenia","volume":"91","author":"Bhatt","year":"2013","journal-title":"European Journal of Haematology"},{"issue":"20","key":"10.1002\/14651858.CD011782.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"issue":"25","key":"10.1002\/14651858.CD011782.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1056\/NEJMoa0806450","article-title":"Outbreak of adverse reactions associated with contaminated heparin","volume":"359","author":"Blossom","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD011782.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJM200103013440902","article-title":"Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis","volume":"344","author":"Breddin","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","article-title":"Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Buller","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0046|cit46","first-page":"33","article-title":"Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis","volume":"1","author":"Capri","journal-title":"Internal and Emergency Medicine"},{"issue":"22","key":"10.1002\/14651858.CD011782.pub2-BIB0047|cit47","first-page":"401","article-title":"Venous thromboembolism in adult hospitalizations - United States 2007-2009","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0167-5273(01)00455-7","article-title":"Enoxaparin in unstable angina patients with renal failure","volume":"80","author":"Collet","year":"2001","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0049|cit49","volume-title":"Systematic Reviews: CRD's Guidance for Undertaking Reviews in Healthcare","author":"Centre for Reviews and Dissemination","year":"2009"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD011782.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clinical Pharmacokinetic"},{"issue":"10","key":"10.1002\/14651858.CD011782.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005134.pub3","article-title":"Pentasaccharides for the prevention of venous thromboembolism","author":"Dong","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0053|cit53","unstructured":"European Medicines Agency Scientific discussion. Product name: Arixtra. EMEA\/H\/C\/403\/II\/24. London, 29 August 2007 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion_-_Variation\/human\/000403\/WC500027742.pdf"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0054|cit54","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. CPMP\/EWP\/707\/98 Rev.1 corr. London, 15 November 2007 www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003301.pdf"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0055|cit55","unstructured":"European Medicines Agency EPAR summary for the public. Arixtra - fondaparinux sodium. EMA\/496403\/2010. EMEA\/H\/C\/000403 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000403\/WC500027736.pdf"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1097-0258(20000715)19:13<1707::AID-SIM491>3.0.CO;2-P","article-title":"Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses","volume":"19","author":"Engels","year":"2000","journal-title":"Statistics in Medicine"},{"issue":"18","key":"10.1002\/14651858.CD011782.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"New England Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD011782.pub2-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001100.pub3","article-title":"Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism","author":"Erkens","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0060|cit60","unstructured":"US Food Drug Administration Arixtra (fondaparinux sodium) injection. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) - August 2009 www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm182229.htm"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ejvs.2002.1778","article-title":"Incidence of diagnosed deep vein thrombosis in the general population: systematic review","volume":"25","author":"Fowkes","year":"2003","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0049-3848(09)70144-6","article-title":"Novel anticoagulants and the future of anticoagulation","volume":"123 Suppl 4","author":"Garcia","year":"2009","journal-title":"Thrombosis Research"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD011782.pub2-BIB0064|cit64","first-page":"531-7","article-title":"Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood","volume":"91","author":"Gerotziafas","year":"2004","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0065|cit65","unstructured":"Food and Drug Administration (FDA). Fondaparinux (Arixtra\u00ae) package insert. Research Triangle Park, NC: GlaxoSmithKline, 2001 www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021345"},{"issue":"9828","key":"10.1002\/14651858.CD011782.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0068|cit68","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0069|cit69","unstructured":"GSK Trial Register www.gsk-clinicalstudyregister.com\/study\/EFC2441#rs"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11239-007-0108-7","article-title":"New oral Xa and IIa inhibitors: updates on clinical trial results","volume":"25","author":"Haas","year":"2008","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"5","key":"10.1002\/14651858.CD011782.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1538-7836.2008.02943.x","article-title":"Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials","volume":"6","author":"Harenberg","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0072|cit72","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD011782.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00002512-199914040-00005","article-title":"Safety of treatment with oral anticoagulants in the elderly. A systematic review","volume":"14","author":"Hutten","year":"1999","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1002\/14651858.CD011782.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ramb.2012.11.004","article-title":"Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction","volume":"59","author":"Junqueira","year":"2013","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"issue":"4","key":"10.1002\/14651858.CD011782.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007557.pub3","article-title":"Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients","author":"Junqueira","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD011782.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2014-09-599498","article-title":"Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study","volume":"125","author":"Kang","year":"2015","journal-title":"Blood"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD011782.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"259-69","DOI":"10.1111\/j.1365-2141.2006.06018.x","article-title":"The management of heparin-induced thrombocytopenia","volume":"133","author":"Keeling","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"9319","key":"10.1002\/14651858.CD011782.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1715-20","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011782.pub2-BIB0081|cit81","first-page":"892","article-title":"Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?","volume":"102","author":"Laux","year":"2009","journal-title":"Thrombosis and Haemostasis"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD011782.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD011782.pub2-BIB0083|cit83","first-page":"I3","article-title":"Initial treatment of venous thromboembolism","volume":"110","author":"McRae","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD011782.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-134-3-200102060-00009","article-title":"Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease","volume":"134","author":"Merli","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.72.Suppl_1.S2","article-title":"A pharmacologic overview of current and emerging anticoagulants","volume":"72","author":"Nutescu","year":"2005","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011782.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2010.03746.x","article-title":"Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion","volume":"8","author":"Paty","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD011782.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.88.4.1730","article-title":"A simple ultrasound approach for detection of recurrent proximal-vein thrombosis","volume":"88","author":"Prandoni","year":"1993","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD011782.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"83","key":"10.1002\/14651858.CD011782.pub2-BIB0089|cit89","first-page":"101","article-title":"Fondaparinux: new indication but still no clear advantage","volume":"15","year":"2006","journal-title":"Prescrire International"},{"issue":"125","key":"10.1002\/14651858.CD011782.pub2-BIB0090|cit90","first-page":"68","article-title":"In France, healthcare products are involved in about half of all serious adverse events related to healthcare","volume":"21","year":"2012","journal-title":"Prescrire International"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0091|cit91","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"14","key":"10.1002\/14651858.CD011782.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2165\/00003495-200464140-00005","article-title":"Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery","volume":"64","author":"Reynolds","year":"2004","journal-title":"Drugs"},{"issue":"3","key":"10.1002\/14651858.CD011782.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0049-3848(02)00031-2","article-title":"Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment","volume":"105","author":"Sanderink","year":"2002","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0094|cit94","unstructured":"Sanofi-Aventis Press release 2009. Discontinuation of development for idrabiotaparinux in atrial fibrillation. 21 December 2009 www.sanofi.se\/l\/se\/sv\/layout.jsp?cnt=94401A59-49CC-406D-BF31-4C46AEDF511F"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2004-05-2010","article-title":"Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin","volume":"105","author":"Savi","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD011782.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"25","key":"10.1002\/14651858.CD011782.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet Alfa for the reversal of Factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD011782.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"e78972","DOI":"10.1371\/journal.pone.0078972","article-title":"Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Song","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.thromres.2008.08.010","article-title":"Brave new world: the current and future use of novel anticoagulants","volume":"123 Suppl 1","author":"Spyropoulos","year":"2008","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2105\/AJPH.2007.126847","article-title":"The importance of external validity","volume":"98","author":"Steckler","year":"2008","journal-title":"American Journal of Public Health"},{"issue":"2","key":"10.1002\/14651858.CD011782.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1524-4733.2006.00085.x","article-title":"Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery","volume":"9","author":"Sullivan","year":"2006","journal-title":"Value Health"},{"issue":"1","key":"10.1002\/14651858.CD011782.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1538-7836.2003.00516.x","article-title":"A novel long-acting synthetic factorXa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation","volume":"2","author":"The PERSIST Investigators","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD011782.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/bcp.12009","article-title":"Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis","volume":"75","author":"Trellu","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD011782.pub2-BIB0104|cit104","first-page":"1671-90","article-title":"The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics","volume":"32","author":"Boeckel","year":"1993","journal-title":"Angewandte Chemie International Edition in English"},{"issue":"11","key":"10.1002\/14651858.CD011782.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD011782.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2518-24","DOI":"10.1001\/archinte.163.20.2518","article-title":"An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients","volume":"163","author":"Warkentin","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011782.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jth.12098","article-title":"Anti-PF4\/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis","volume":"11","author":"Warkentin","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"9 Suppl 1","key":"10.1002\/14651858.CD011782.pub2-BIB0108|cit108","first-page":"I19","article-title":"New anticoagulants for treatment of venous thromboembolism","volume":"110","author":"Weitz","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011782.pub2-BIB0109|cit109","unstructured":"World Health Organization (WHO) Glossary of pharmacovigilance terms https:\/\/www.who-umc.org\/global-pharmacovigilance\/global-pharmacovigilance\/glossary\/"},{"issue":"7","key":"10.1002\/14651858.CD011782.pub2-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011782","article-title":"Pentasaccharides for the treatment of deep vein thrombosis","author":"Brandao","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011782.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T11:51:00Z","timestamp":1702036260000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011782.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,2]]},"references-count":110,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011782.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,2]]}}}